US5266575A
(en)
*
|
1991-11-06 |
1993-11-30 |
Minnesota Mining And Manufacturing Company |
2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
|
US5395937A
(en)
*
|
1993-01-29 |
1995-03-07 |
Minnesota Mining And Manufacturing Company |
Process for preparing quinoline amines
|
EP0708772B1
(en)
*
|
1993-07-15 |
2000-08-23 |
Minnesota Mining And Manufacturing Company |
IMIDAZO [4,5-c]PYRIDIN-4-AMINES
|
US5352784A
(en)
*
|
1993-07-15 |
1994-10-04 |
Minnesota Mining And Manufacturing Company |
Fused cycloalkylimidazopyridines
|
US5648516A
(en)
*
|
1994-07-20 |
1997-07-15 |
Minnesota Mining And Manufacturing Company |
Fused cycloalkylimidazopyridines
|
US5482936A
(en)
*
|
1995-01-12 |
1996-01-09 |
Minnesota Mining And Manufacturing Company |
Imidazo[4,5-C]quinoline amines
|
US6133547A
(en)
*
|
1996-09-05 |
2000-10-17 |
Medtronic, Inc. |
Distributed activator for a two-dimensional shape memory alloy
|
US5939090A
(en)
*
|
1996-12-03 |
1999-08-17 |
3M Innovative Properties Company |
Gel formulations for topical drug delivery
|
JPH10298181A
(ja)
*
|
1997-04-25 |
1998-11-10 |
Sumitomo Pharmaceut Co Ltd |
タイプ2ヘルパーt細胞選択的免疫応答抑制剤
|
UA75622C2
(en)
*
|
2000-12-08 |
2006-05-15 |
3M Innovative Properties Co |
Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
|
EP1541572A1
(en)
*
|
2000-12-08 |
2005-06-15 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
US6664264B2
(en)
*
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
GB0211649D0
(en)
|
2002-05-21 |
2002-07-03 |
Novartis Ag |
Organic compounds
|
CA2493227A1
(en)
*
|
2002-07-23 |
2004-01-29 |
Biogal Gyogyszergyar Rt. |
Preparation of 1h-imidazo[4,5-c]quinolin-4-amines via1h-imidazo [4,5-c]quinolin-4-phthalimide intermediates
|
CA2540541C
(en)
|
2003-10-03 |
2012-03-27 |
3M Innovative Properties Company |
Alkoxy substituted imidazoquinolines
|
AU2004293078B2
(en)
|
2003-11-25 |
2012-01-19 |
3M Innovative Properties Company |
Substituted imidazo ring systems and methods
|
AU2005283085B2
(en)
*
|
2004-06-18 |
2012-06-21 |
3M Innovative Properties Company |
Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
US8080560B2
(en)
|
2004-12-17 |
2011-12-20 |
3M Innovative Properties Company |
Immune response modifier formulations containing oleic acid and methods
|
US9248127B2
(en)
|
2005-02-04 |
2016-02-02 |
3M Innovative Properties Company |
Aqueous gel formulations containing immune response modifiers
|
LT2351772T
(lt)
|
2005-02-18 |
2016-10-10 |
Glaxosmithkline Biologicals Sa |
Baltymai ir nukleorūgštys iš su meningitu/sepsiu susijusių escherichia coli
|
NZ580974A
(en)
|
2005-02-18 |
2011-05-27 |
Novartis Vaccines & Diagnostic |
Immunogens from uropathogenic escherichia coli
|
CA2598656A1
(en)
|
2005-02-23 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Hydroxyalkyl substituted imidazoquinoline compounds and methods
|
EP1851224A2
(en)
*
|
2005-02-23 |
2007-11-07 |
3M Innovative Properties Company |
Hydroxyalkyl substituted imidazoquinolines
|
CA2598437A1
(en)
|
2005-02-23 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Method of preferentially inducing the biosynthesis of interferon
|
CA2602590A1
(en)
|
2005-04-01 |
2006-10-12 |
Coley Pharmaceutical Group, Inc. |
1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
|
JP2009514839A
(ja)
|
2005-11-04 |
2009-04-09 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
サイトカイン誘導剤を含むアジュバントインフルエンザワクチン
|
CN102727885A
(zh)
|
2005-11-04 |
2012-10-17 |
诺华疫苗和诊断有限公司 |
包含颗粒佐剂和免疫增强剂组合的流感疫苗
|
US20090304742A1
(en)
|
2005-11-04 |
2009-12-10 |
Novartis Vaccines And Diagnostics Srl |
Influenza vaccines with reduced amount of emulsion adjuvant
|
AU2006311871B2
(en)
*
|
2005-11-04 |
2011-03-03 |
3M Innovative Properties Company |
Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods
|
DK2368572T3
(da)
|
2005-11-04 |
2020-05-25 |
Seqirus Uk Ltd |
Adjuvansvacciner med ikke-virionantigener fremstillet fra influenza-virusser dyrket i cellekultur
|
WO2007085969A2
(en)
|
2006-01-27 |
2007-08-02 |
Novartis Vaccines And Diagnostics Gmbh & Co Kg |
Influenza vaccines containing hemagglutinin and matrix proteins
|
JP2009534303A
(ja)
|
2006-03-24 |
2009-09-24 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー |
冷蔵しないインフルエンザワクチンの保存
|
EP2019686B1
(en)
|
2006-03-31 |
2012-07-11 |
Novartis AG |
Combined mucosal and parenteral immunization against hiv
|
PL2054431T3
(pl)
|
2006-06-09 |
2012-07-31 |
Novartis Ag |
Konformery adhezyn bakteryjnych
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
AU2007279376B2
(en)
|
2006-07-31 |
2012-09-06 |
Wirra Ip Pty Ltd |
Immune response modifier compositions and methods
|
WO2008020330A2
(en)
|
2006-08-16 |
2008-02-21 |
Novartis Ag |
Immunogens from uropathogenic escherichia coli
|
CA3016948A1
(en)
|
2006-09-11 |
2008-03-20 |
Seqirus UK Limited |
Making influenza virus vaccines without using eggs
|
NZ577405A
(en)
|
2006-12-06 |
2012-08-31 |
Novartis Ag |
Vaccines including antigen from four strains of influenza virus
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
PL2155743T3
(pl)
*
|
2007-05-08 |
2013-01-31 |
Astrazeneca Ab |
Imidazochinoliny o właściwościach immunomodulacyjnych
|
CA2692200A1
(en)
|
2007-06-27 |
2008-12-31 |
Novartis Ag |
Low-additive influenza vaccines
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
CA2716706C
(en)
*
|
2008-03-03 |
2014-02-18 |
Irm Llc |
Compounds and compositions as tlr activity modulators
|
EP2889042A3
(en)
|
2008-03-18 |
2015-10-14 |
Novartis AG |
Improvements in preparation of influenza virus vaccine antigens
|
DK2386557T3
(en)
*
|
2008-03-24 |
2018-04-23 |
Biontech Ag |
Newly substituted imidazoquinolines
|
CN102438650A
(zh)
|
2009-03-06 |
2012-05-02 |
诺华有限公司 |
衣原体抗原
|
BRPI1013780B8
(pt)
|
2009-04-14 |
2022-10-04 |
Novartis Ag |
Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
|
USH2284H1
(en)
|
2009-04-27 |
2013-09-03 |
Novartis Ag |
Vaccines for protecting against influenza
|
WO2011004263A2
(en)
|
2009-07-07 |
2011-01-13 |
Novartis Ag |
Conserved escherichia coli immunogens
|
EP3988115A3
(en)
|
2009-07-15 |
2022-08-17 |
GlaxoSmithKline Biologicals S.A. |
Rsv f protein compositions and methods for making same
|
AU2010272243A1
(en)
|
2009-07-16 |
2012-03-08 |
Novartis Ag |
Detoxified Escherichia coli immunogens
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
WO2011084726A1
(en)
*
|
2009-12-21 |
2011-07-14 |
3M Innovative Properties Company |
BIS [4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM] 4-[(3-CARBOXYLATO-2-HYDROXYNAPHTHALEN-1-YL)METHYL]-3-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS
|
WO2011084725A1
(en)
*
|
2009-12-21 |
2011-07-14 |
3M Innovative Properties Company |
4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM 1-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS
|
EP2519265B1
(en)
|
2009-12-30 |
2018-11-14 |
GlaxoSmithKline Biologicals SA |
Polysaccharide immunogens conjugated to e. coli carrier proteins
|
US20110293700A1
(en)
|
2010-05-26 |
2011-12-01 |
Selecta Biosciences, Inc. |
Nanocarrier compositions with uncoupled adjuvant
|
CA2801149A1
(en)
|
2010-06-01 |
2011-12-08 |
Novartis Ag |
Concentration of vaccine antigens without lyophilization
|
PL2575873T3
(pl)
|
2010-06-01 |
2016-06-30 |
Novartis Ag |
Zatężanie i liofilizacja antygenów szczepionkowych grypy
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
CA2808965C
(en)
|
2010-08-20 |
2020-01-07 |
Novartis Ag |
Soluble needle arrays for delivery of influenza vaccines
|
WO2012061717A1
(en)
|
2010-11-05 |
2012-05-10 |
Selecta Biosciences, Inc. |
Modified nicotinic compounds and related methods
|
PL2667892T3
(pl)
|
2011-01-26 |
2019-09-30 |
Glaxosmithkline Biologicals Sa |
Schemat szczepień przeciwko rsv
|
LT2707385T
(lt)
|
2011-05-13 |
2017-12-11 |
Glaxosmithkline Biologicals Sa |
Iš anksto sulieti rsv f antigenai
|
US8728486B2
(en)
|
2011-05-18 |
2014-05-20 |
University Of Kansas |
Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
|
EP2729178A1
(en)
|
2011-07-08 |
2014-05-14 |
Novartis AG |
Tyrosine ligation process
|
CN104080479B
(zh)
|
2011-11-07 |
2019-11-05 |
葛兰素史密丝克莱恩生物有限公司 |
包括spr0096和spr2021抗原的运载体分子
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
JP2015532276A
(ja)
|
2012-10-02 |
2015-11-09 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
非直鎖状糖コンジュゲート
|
PL2925355T3
(pl)
|
2012-11-30 |
2018-06-29 |
Glaxosmithkline Biologicals S.A. |
Antygeny pseudomonas i połączenia antygenów
|
DK2950649T3
(da)
*
|
2013-02-01 |
2020-05-04 |
Wellstat Therapeutics Corp |
Aminforbindelser med antiinflammations-, antisvampe-, antiparasit- og anticanceraktivitet
|
EP2870974A1
(en)
|
2013-11-08 |
2015-05-13 |
Novartis AG |
Salmonella conjugate vaccines
|
BE1022744B1
(fr)
|
2014-03-26 |
2016-08-29 |
Glaxosmithkline Biologicals Sa |
Antigenes staphylococciques mutants
|
ES2804101T3
(es)
|
2014-04-22 |
2021-02-03 |
Hoffmann La Roche |
Compuestos de 4-amino-imidazoquinolina
|
HUE042563T2
(hu)
|
2015-03-06 |
2019-07-29 |
Hoffmann La Roche |
Benzazepin-dikarboxamid vegyületek
|
WO2017046675A1
(en)
*
|
2015-09-14 |
2017-03-23 |
Pfizer Inc. |
Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors
|
EP3350168B1
(en)
|
2015-09-17 |
2019-12-18 |
H. Hoffnabb-La Roche Ag |
Sulfinylphenyl or sulfonimidoylphenyl benzazepines
|
EP3464245B1
(en)
|
2016-05-23 |
2020-10-14 |
H. Hoffnabb-La Roche Ag |
Benzazepine dicarboxamide compounds with tertiary amide function
|
WO2017202703A1
(en)
|
2016-05-23 |
2017-11-30 |
F. Hoffmann-La Roche Ag |
Benzazepine dicarboxamide compounds with secondary amide function
|
EP3468963B1
(en)
|
2016-06-12 |
2021-10-27 |
F. Hoffmann-La Roche AG |
Dihydropyrimidinyl benzazepine carboxamide compounds
|
TWI674261B
(zh)
*
|
2017-02-17 |
2019-10-11 |
美商英能腫瘤免疫股份有限公司 |
Nlrp3 調節劑
|
EP3625231B1
(en)
|
2017-05-19 |
2022-07-20 |
Superb Wisdom Limited |
Derivatives of resiquimod
|
WO2018232725A1
(en)
*
|
2017-06-23 |
2018-12-27 |
Birdie Biopharmaceuticals, Inc. |
PHARMACEUTICAL COMPOSITIONS
|
WO2020255038A1
(en)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
|